Mizuho analyst Graig Suvannavejh raised the firm’s price target on Insmed (INSM) to $196 from $165 and keeps an Outperform rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed assumed with an Overweight at Cantor Fitzgerald
- INSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insmed’s CEDAR Study: A Potential Game-Changer for Hidradenitis Suppurativa Treatment
- Insmed’s Phase 1 Study on TPIP Formulations: A Potential Game-Changer in Drug Delivery
- Insmed’s New Phase 3 Study: A Potential Game Changer for PH-ILD Treatment?